Justin D Wong

Address:

1362 41 Ave, San Francisco, CA 94122

VIN:

5FNRL38619B038781

Make:

HONDA

Model:

ODYSSEY

Year:

2009

US Patent:

7982014, Jul 19, 2011

Filed:

Jan 5, 2010

Appl. No.:

12/652720

Inventors:

Lewis T. Williams - Mill Valley CA, US
Elizabeth Bosch - Cupertino CA, US
Stephen Doberstein - San Francisco CA, US
Kevin Hestir - Kensington CA, US
Diane Hollenbaugh - Mountain View CA, US
Ernestine Lee - Kensington CA, US
Minmin Qin - Pleasanton CA, US
Ali Sadra - San Mateo CA, US
Justin Wong - Oakland CA, US
Ge Wu - La Canada CA, US
Hongbing Zhang - Albany CA, US

Assignee:

Five Prime Therapeutics, Inc. - San Francisco CA

International Classification:

A61K 38/00
A61K 38/18
A61K 39/00

US Classification:

5303873, 4241341, 4241851, 4241921, 514 91, 435 697

Abstract:

The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

US Patent:

8404810, Mar 26, 2013

Filed:

Feb 20, 2007

Appl. No.:

12/279703

Inventors:

Kevin Hestir - Kensington CA, US
Justin Wong - Oakland CA, US

Assignee:

Five Prime Therapeutics, Inc. - South San Francisco CA

International Classification:

C07K 14/00

US Classification:

5303871, 5303877, 5303873

Abstract:

This invention relates to the polynucleotides and the encoded polypeptides, including novel sequences, of human or non-human primate genes that are amplified in breast and/or other tumor tissues melanoma, as compared to the corresponding normal tissue. The invention also relates to modulators of such polynucleotides and polypeptides, for example, antibodies, that specifically bind to and/or interfere with the activity of this polypeptide, polynucleotide, its fragments, variants, and antagonists. The invention further relates to compositions containing such a polypeptide, polynucleotide, or modulators thereof and uses of such compositions in methods of treating or preventing cancer, by detecting this polynucleotide, polypeptide, or antibodies thereto in patient samples. The invention also provides diagnostic tests for breast cancer and melanoma, by identifying polypeptides and polynucleotides encoded by the cDNA sequence of the invention that correlate with those disorders.

US Patent:

8580936, Nov 12, 2013

Filed:

Sep 7, 2011

Appl. No.:

13/227398

Inventors:

Lewis T. Williams - Mill Valley CA, US
Elizabeth Bosch - Cupertino CA, US
Stephen Doberstein - San Francisco CA, US
Kevin Hestir - Kensington CA, US
Diane Hollenbaugh - Mountain View CA, US
Ernestine Lee - Kensington CA, US
Minmin Qin - Pleasanton CA, US
Ali Sadra - San Mateo CA, US
Justin Wong - Oakland CA, US
Ge Wu - La Canada CA, US
Hongbing Zhang - Albany CA, US

Assignee:

Five Prime Therapeutics, Inc. - South San Francisco CA

International Classification:

C07H 21/04
A61K 39/00
C12P 21/02
C12N 5/10
C12N 15/00

US Classification:

536 234, 4241921, 4241781, 435 697, 435455, 5303873

Abstract:

The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

US Patent:

8206715, Jun 26, 2012

Filed:

May 4, 2011

Appl. No.:

13/100990

Inventors:

Justin Wong - San Francisco CA, US
Maximiliano Vasquez - Palo Alto CA, US

Assignee:

Five Prime Therapeutics, Inc. - South San Francisco CA

International Classification:

A61K 39/395
C07K 16/00
C12P 21/08

US Classification:

4241431, 4241301, 5303971, 5303973, 53038822

Abstract:

Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.

US Patent:

20030087288, May 8, 2003

Filed:

Sep 16, 2002

Appl. No.:

10/244715

Inventors:

James Keck - Redwood City CA, US
Justin Wong - Oakland CA, US

International Classification:

C12Q001/68
G01N033/53

US Classification:

435/006000, 435/007100

Abstract:

Methods and compositions for identifying a gene or genes associated with the generation of a specific cellular phenotype or a specific cellular response using combinatorial libraries of catalytic RNA directed against RNA sequences encoding structural or functional polypeptide motifs. The invention is exemplified by use of a combinatorial ribozyme library to target sequence in mRNAs encoding zinc finger, protein kinase and integrin motifs.

US Patent:

20060084799, Apr 20, 2006

Filed:

Sep 24, 2004

Appl. No.:

10/948571

Inventors:

Lewis Williams - Mill Valley CA, US
Keting Chu - Woodside CA, US
Ernestine Lee - Kensington CA, US
Kevin Hestir - Kensington CA, US
Justin Wong - Oakland CA, US
Stephen Doberstein - San Francisco CA, US

International Classification:

C07K 14/705
A01K 67/00
C07H 21/04
C12P 21/06
C12N 5/06

US Classification:

536023500, 435069100, 435320100, 435325000, 530350000, 800008000

Abstract:

The invention provides novel human full-length cDNA clones, novel polynucleotides, related polypeptides, related nucleic acid and polypeptide compositions, and related modulators, such as antibodies and small molecule modulators. The invention also provides methods to make and use these cDNA clones, polynucleotides, polypeptides, related compositions, and modulators. These methods include diagnostic, prophylactic and therapeutic applications. The compositions and methods of the invention are useful in treating proliferative disorders, e.g., cancers, and inflammatory, immune, bacterial, and viral disorders.

US Patent:

20070248605, Oct 25, 2007

Filed:

Dec 17, 2004

Appl. No.:

10/583146

Inventors:

Kevin Hestir - Kensington CA, US
Kristen Pierce - Burlingame CA, US
Lewis Williams - Burlingame CA, US
Lorianne Masuoka - Oakland CA, US
Justin Wong - Oakland CA, US
Keting Chu - Woodside CA, US

Assignee:

Five Prime Therapetutics, Inc. - South San Francisco CA

International Classification:

A61K 39/395
C07K 16/22
G01N 33/53

US Classification:

424139100, 435007100, 530387900

Abstract:

A composition is provided that contains a polypeptide and a modulator or a cell comprising the polypeptide and a modulator, where the modulator specifically interferes with the activity of the polypeptide, and the polypeptide is either FGFR3 or FGFR4, inclusive of all polymorphic forms and variants thereof. The modulator can be an antibody or active fragments thereof, a small molecule drug, an RNAi molecule, an antisense molecule or a ribozyme. A method of treatment of tumors in a subject is also provided where an antagonist of FGFR3 or FGFR4 is administered to the subject.

US Patent:

20070264277, Nov 15, 2007

Filed:

Jul 21, 2005

Appl. No.:

11/632319

Inventors:

Dirk Behrens - San Francisco CA, US
Elizabeth Bosch - San Francisco CA, US
Stephen Doberstein - San Francisco CA, US
Robert Halenbeck - San Francisco CA, US
Kevin Hestir - San Francisco CA, US
Min Huang - San Francisco CA, US
Ernestine Lee - San Francisco CA, US
Haishan Lin - San Francisco CA, US
Thomas Linnemann - San Francisco CA, US
Shannon Marshall - San Francisco CA, US
Justin Wong - San Francisco CA, US
Ge Wu - San Francisco CA, US
Aileen Zhou - San Francisco CA, US

International Classification:

A61K 39/00
A61K 38/00
C07H 21/00
C07K 14/00
C07K 16/18
C12N 15/00
C12N 15/87
C12N 5/06
C12P 1/00
G01N 33/53

US Classification:

424185100, 435320100, 435325000, 435375000, 435466000, 435069100, 435007100, 514002000, 530350000, 530387100, 536023100

Abstract:

Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.